View:

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 7, 2017

 


 

Catabasis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 


 

Delaware

 

001-37467

 

26-3687168

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

One Kendall Square
Bldg. 1400E, Suite B14202

Cambridge, Massachusetts 02139

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (617) 349-1971

 

None

(Former Name or Former Address, if Changed Since Last Report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 



 

Item 5.02.                Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As disclosed in the proxy statement of Catabasis Pharmaceuticals, Inc. (the “Company”) relating to the Company’s Annual Meeting of Stockholders, upon his election as a Class II director of the Company at the Annual Meeting of Stockholders held on June 7, 2017 (as described under Item 5.07 below), Kenneth Bate, who previously served as a Class III director of the Company, resigned as Class III director.

 

Item 5.07.                Submission of Matters to a Vote of Security Holders.

 

The Company held its Annual Meeting of Stockholders on June 7, 2017.  The following is a summary of the matters voted on at that meeting.

 

a)                                     The stockholders of the Company elected Kenneth Bate and Jean George as Class II directors to the Company’s Board of Directors, each to serve for a three-year term expiring at the annual meeting of stockholders to be held in 2020.  The results of the stockholders’ vote with respect to the election of Class II directors were as follows:

 

Name

 

Votes For

 

Votes
Withheld

 

Broker Non-
Votes

 

Votes
Abstaining

 

Kenneth Bate

 

8,724,376

 

326,481

 

6,698,090

 

 

Jean George

 

8,962,069

 

88,788

 

6,698,090

 

 

 

b)                                     The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.  The results of the stockholders’ vote with respect to the ratification of such appointment were as follows:

 

Votes For

 

Votes Against

 

Broker Non-Votes

 

Votes Abstaining

 

15,482,796

 

253,600

 

0

 

12,551

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CATABASIS PHARMACEUTICALS, INC.

 

 

 

Date: June 12, 2017

By:

/s/ Jill C. Milne

 

 

Jill C. Milne, Ph.D.

 

 

President and Chief Executive Officer

 

3